

# Human HLA-A\*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein



Cat. No. MHC-HM423T

## Description

<b>Source</b>	Recombinant Human KRAS WT(HLA-A*03:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.
<b>Accession</b>	NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAGGVGK
<b>Molecular Weight</b>	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.


## Assay Data

### Bis-Tris PAGE



Human HLA-A\*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer on Bis-Tris PAGE under under Non reducing (N) condition. The purity is greater than 95%.

### SEC-HPLC



The purity of Human HLA-A\*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.